Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
540

Inclusion Criteria

Bilirubin less than or equal to 1.5 x institutional/laboratory upper limit of normal (ULN)
Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Patients must have signed an approved informed consent and authorization permitting release of personal health information; individuals with impaired decision-making capacity are not eligible to participate on the study
...
Bilirubin less than or equal to 1.5 x institutional/laboratory upper limit of normal (ULN)
Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Patients must have signed an approved informed consent and authorization permitting release of personal health information; individuals with impaired decision-making capacity are not eligible to participate on the study
Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma
Patients may have received prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy
Platelets greater than or equal to 100,000/mcl
Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2
Patients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least one week prior to the first date of study therapy
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN
Alkaline phosphatase less than or equal to 2.5 x ULN
Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.)
Patients must be able to swallow and retain orally-administered medication
Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl
Creatinine less than 1.4 mg/dl

Exclusion Criteria

Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last three years
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Any condition associated with increased risk of metformin-associated lactic acidosis; (e.g. congestive heart failure defined as New York Heart Association [NYHA] class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)
...
Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last three years
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Any condition associated with increased risk of metformin-associated lactic acidosis; (e.g. congestive heart failure defined as New York Heart Association [NYHA] class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)
Patients who are pregnant or nursing; if patients are of reproductive age and have not undergone hysterectomy, they must use an effective contraceptive method for the duration of this study
Patients must NOT be taking metformin or have been on metformin in the past 6 months

Summary

Conditions
  • Stage IIIC Uterine Corpus Cancer AJCC v7
  • Endometrial Adenocarcinoma
  • Endometrial Clear Cell Adenocarcinoma
  • Endometrial Serous Adenocarcinoma
  • Endometrial Undifferentiated Carcinoma
  • Recurrent Uterine Corpus Carcinoma
  • Stage III Uterine Corpus Cancer AJCC v7
  • Stage IIIA Uterine Corpus Cancer AJCC v7
  • Stage IIIB Uterine Corpus Cancer AJCC v7
  • Stage IVB Uterine Corpus Cancer AJCC v7
  • Stage IV Uterine Corpus Cancer AJCC v7
  • Stage IVA Uterine Corpus Cancer AJCC v7
Type
Interventional
Phase
Phase 2 & Phase 3
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Participant, Investigator)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Only females

Description

PRIMARY OBJECTIVES: I. To determine if the addition of metformin (metformin hydrochloride) to the standard regimen of carboplatin and paclitaxel prolongs progression-free survival (PFS) in women with advanced or recurrent endometrial cancer. (Phase II) II. To determine if the addition of metformin t...

PRIMARY OBJECTIVES: I. To determine if the addition of metformin (metformin hydrochloride) to the standard regimen of carboplatin and paclitaxel prolongs progression-free survival (PFS) in women with advanced or recurrent endometrial cancer. (Phase II) II. To determine if the addition of metformin to the standard regimen of carboplatin and paclitaxel prolongs overall survival (OS) in the same population if a phase III study is conducted. Both clinical trials (Phase II and III) will utilize OS as a primary endpoint if a phase III trial is opened. SECONDARY OBJECTIVES: I. To estimate the proportion of patients with objective response (response rate [RR]) in the population of patients with measurable disease by treatment. II. To estimate the duration of response in the population of patients with measurable disease who respond by treatment. III. To estimate overall survival (OS) and relative hazards of death for each treatment arm if the study stops after the phase II trial is completed. If the study continues with a phase III clinical trial, then PFS will be a secondary endpoint. IV. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) for each treatment arm. V. To estimate possible differences in RR, PFS, OS, and toxicity rates for the treatment regimens by the patients' level of obesity. TERTIARY OBJECTIVES: I. To test whether PIK3CA mutations/amplifications, PTEN mutations or PIK3R1/PIK3R2 mutations have a lower hazard of progression or death (PFS endpoint) among patients who are treated with metformin. II. To test whether higher expression of MATE 2 is associated with a lower hazard of progression or death (PFS endpoint) among patients who are treated with metformin. III. To explore the association of metabolic factors (i.e. body mass index [BMI], hip-to-waist ratio, diabetes status, hemoglobin A1c [HgbA1C], fasting insulin and glucose levels, homeostatic model assessment [HOMA] scores) with treatment response to metformin/paclitaxel/carboplatin, PFS, and OS. IV. To test whether genomic profiles (i.e. PIK3CA mutations/amplifications, PTEN mutations or PIK3R1/PIK3R2 mutations) differ between the tumors of obese and non-obese endometrial cancer (EC) patients. V. To correlate expression of key targets of the insulin/IGF-1/mTOR signaling pathway (p-IGF1R, p-S6 and p-4EBP-1) with treatment response to metformin/paclitaxel/carboplatin, PFS, OS and obesity status. VI. To determine if the genetic variants of the metformin transporters correspond with treatment response to metformin/paclitaxel/carboplatin, PFS and OS. VII. To estimate differences in physical functioning, physical activity, and fatigue between treatment arms. VIII. To explore the association between metabolic factors (i.e., BMI, hip-to-waist ratio, diabetes status, HgbA1C, fasting insulin and glucose levels, HOMA scores) and physical functioning, physical activity, and fatigue. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride orally (PO) twice daily (BID) (approximately 10-12 hours apart) on days 1-21 (once daily [QD] in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In both arms, patients who achieve stable disease (SD) or partial response (PR) and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Inclusion Criteria

Bilirubin less than or equal to 1.5 x institutional/laboratory upper limit of normal (ULN)
Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Patients must have signed an approved informed consent and authorization permitting release of personal health information; individuals with impaired decision-making capacity are not eligible to participate on the study
...
Bilirubin less than or equal to 1.5 x institutional/laboratory upper limit of normal (ULN)
Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
Patients must have signed an approved informed consent and authorization permitting release of personal health information; individuals with impaired decision-making capacity are not eligible to participate on the study
Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma
Patients may have received prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy
Platelets greater than or equal to 100,000/mcl
Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2
Patients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least one week prior to the first date of study therapy
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN
Alkaline phosphatase less than or equal to 2.5 x ULN
Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.)
Patients must be able to swallow and retain orally-administered medication
Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl
Creatinine less than 1.4 mg/dl

Exclusion Criteria

Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last three years
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Any condition associated with increased risk of metformin-associated lactic acidosis; (e.g. congestive heart failure defined as New York Heart Association [NYHA] class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)
...
Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer are excluded if there is any evidence of other malignancy being present within the last three years
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Any condition associated with increased risk of metformin-associated lactic acidosis; (e.g. congestive heart failure defined as New York Heart Association [NYHA] class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)
Patients who are pregnant or nursing; if patients are of reproductive age and have not undergone hysterectomy, they must use an effective contraceptive method for the duration of this study
Patients must NOT be taking metformin or have been on metformin in the past 6 months

Locations

Marshalltown, Iowa, 50158
Fargo, North Dakota, 58122
Michigan City, Indiana, 46360
San Francisco, California, 94115
Albuquerque, New Mexico, 87106
...
Marshalltown, Iowa, 50158
Fargo, North Dakota, 58122
Michigan City, Indiana, 46360
San Francisco, California, 94115
Albuquerque, New Mexico, 87106
Battle Creek, Michigan, 49017
Richmond, Virginia, 23298
Los Angeles, California, 90048
Iowa City, Iowa, 52242
Dallas, Texas, 75390
Waukesha, Wisconsin, 53188
Birmingham, Alabama, 35233
Kalamazoo, Michigan, 49007
Jacksonville, North Carolina, 28546
Minneapolis, Minnesota, 55455
Logan, Utah, 84321
Saint Johnsbury, Vermont, 05819
Madison, Wisconsin, 53792
Oklahoma City, Oklahoma, 73104
Boise, Idaho, 83706
San Francisco, California, 94158
Clive, Iowa, 50325
Westville, Indiana, 46391
Philadelphia, Pennsylvania, 19111
Baltimore, Maryland, 21204
Hinsdale, Illinois, 60521
Chapel Hill, North Carolina, 27599
San Leandro, California, 94577
Wilkes-Barre, Pennsylvania, 18711
Phoenix, Arizona, 85016
Sugar Land, Texas, 77478
Seattle, Washington, 98195
Orlando, Florida, 32803
Carthage, Illinois, 62321
Colorado Springs, Colorado, 80907
Ames, Iowa, 50010
Orange, California, 92868
Honolulu, Hawaii, 96817
Kearney, Nebraska, 68847
Houston, Texas, 77079
Providence, Rhode Island, 02905
Winston-Salem, North Carolina, 27103
Tucson, Arizona, 85704
Roseville, California, 95661
Glens Falls, New York, 12801
Bemidji, Minnesota, 56601
Canton, Illinois, 61520
Orange, Connecticut, 06477
Valhalla, New York, 10595
Kernersville, North Carolina, 27284
Sioux Falls, South Dakota, 57117-5134
Fargo, North Dakota, 58122
Anderson, South Carolina, 29621
Jefferson, Iowa, 50129
Tulsa, Oklahoma, 74146
Voorhees, New Jersey, 08043
Yorkville, Illinois, 60560
Springfield, Missouri, 65807
Provo, Utah, 84604
Lewisburg, Pennsylvania, 17837
Bronx, New York, 10461
Saint Louis, Missouri, 63141
Wilkesboro, North Carolina, 28659
Cedar City, Utah, 84720
Farmington Hills, Michigan, 48334
Princeton, Illinois, 61356
San Francisco, California, 94115
Statesville, North Carolina, 28625
Kalispell, Montana, 59901
Highland Park, Illinois, 60035
O'Fallon, Illinois, 62269
Saint Paul, Minnesota, 55102
State College, Pennsylvania, 16801
Flint, Michigan, 48503
Fairfield, Connecticut, 06824
Fort Dodge, Iowa, 50501
Michigan City, Indiana, 46360
Cleveland, Ohio, 44106
Commack, New York, 11725
Concord, North Carolina, 28025
Lowell, Massachusetts, 01854
Walnut Creek, California, 94598
Baton Rouge, Louisiana, 70817
Houston, Texas, 77070
New York, New York, 10032
Baltimore, Maryland, 21215
Gettysburg, Pennsylvania, 17325
Lihue, Hawaii, 96766
Rehoboth Beach, Delaware, 19971
Philadelphia, Pennsylvania, 19140
Grand Rapids, Michigan, 49503
Urbana, Illinois, 61801
Danville, Illinois, 61832
Mattoon, Illinois, 61938
Saint Louis, Missouri, 63110
Tacoma, Washington, 98405
Dover, New Hampshire, 03820
Des Moines, Iowa, 50314
Decatur, Illinois, 62526
Los Angeles, California, 90095
Santa Clara, California, 95051
Torrington, Connecticut, 06790
Saint Louis, Missouri, 63110
Lebanon, New Hampshire, 03756
Skokie, Illinois, 60076
Thomasville, North Carolina, 27360
Knoxville, Tennessee, 37920
Albuquerque, New Mexico, 87102
Springfield, Missouri, 65804
Honolulu, Hawaii, 96817
Peru, Illinois, 61354
Philadelphia, Pennsylvania, 19107
Cape Girardeau, Missouri, 63703
Falls Church, Virginia, 22042
Green Bay, Wisconsin, 54303
Dallas, Texas, 75231
Port Huron, Michigan, 48060
Dayton, Ohio, 45405
Lewistown, Pennsylvania, 17044
Seattle, Washington, 98133
Saginaw, Michigan, 48601
Sylvania, Ohio, 43560
Chattanooga, Tennessee, 37403
Wisconsin Rapids, Wisconsin, 54494
Bismarck, North Dakota, 58501
Greensburg, Pennsylvania, 15601
Evanston, Illinois, 60201
Rolla, Missouri, 65401
Omaha, Nebraska, 68114
Reno, Nevada, 89502
Eureka, Illinois, 61530
Mount Airy, North Carolina, 27030
Wilmington, North Carolina, 28401
Basking Ridge, New Jersey, 07920
Orland Park, Illinois, 60462
New York, New York, 10065
Milwaukee, Wisconsin, 53226
Columbus, Ohio, 43214
Newark, Delaware, 19713
Harrison, New York, 10604
Greenville, South Carolina, 29601
Philadelphia, Pennsylvania, 19104
Flint, Michigan, 48503
Honolulu, Hawaii, 96813
Charlotte, North Carolina, 28204
Boston, Massachusetts, 02111
Detroit, Michigan, 48201
West Reading, Pennsylvania, 19611
Weston, Wisconsin, 54476
Jackson, Mississippi, 39216
Bloomington, Illinois, 61704
Honolulu, Hawaii, 96826
Tucson, Arizona, 85710
Arlington Heights, Illinois, 60005
Elk Grove Village, Illinois, 60007
Saint Louis Park, Minnesota, 55416
Fairfax, Virginia, 22031
Honolulu, Hawaii, 96817
Dayton, Ohio, 45415
Cleveland, Ohio, 44195
Rapid City, South Dakota, 57701
Green Bay, Wisconsin, 54301
Boston, Massachusetts, 02215
Mason City, Iowa, 50401
Charlotte, North Carolina, 28203
Saint Louis Park, Minnesota, 55416
Columbus, Ohio, 43215
Vallejo, California, 94589
Jacksonville, North Carolina, 28546
Uniontown, Pennsylvania, 15401
Hendersonville, North Carolina, 28792
Mishawaka, Indiana, 46545
Manitowoc, Wisconsin, 54221
Indianapolis, Indiana, 46260
Springfield, Illinois, 62781
Atlanta, Georgia, 30342
Waukesha, Wisconsin, 53188
Gainesville, Georgia, 30501
South Bend, Indiana, 46601
Dayton, Ohio, 45409
New Lenox, Illinois, 60451
La Jolla, California, 92093
Sleepy Hollow, New York, 10591
New Orleans, Louisiana, 70121
Chicago, Illinois, 60612
Baltimore, Maryland, 21287
Clinton, North Carolina, 28328
Green Bay, Wisconsin, 54301-3526
Austin, Texas, 78705
Escanaba, Michigan, 49829
Scarborough, Maine, 04074
Macomb, Illinois, 61455
Wilmington, Delaware, 19801
South San Francisco, California, 94080
Austin, Texas, 78745
Ann Arbor, Michigan, 48109
Gainesville, Florida, 32610
Uniondale, New York, 11553
Honolulu, Hawaii, 96813
Reno, Nevada, 89502
Trumbull, Connecticut, 06611
Seattle, Washington, 98133
Lexington, Kentucky, 40536
Walnut Creek, California, 94596
Springfield, Illinois, 62702
Columbus, Ohio, 43210
Los Angeles, California, 90033
Goldsboro, North Carolina, 27534
Palo Alto, California, 94301
Salt Lake City, Utah, 84106
Hazleton, Pennsylvania, 18201
Pottsville, Pennsylvania, 17901
Sturgeon Bay, Wisconsin, 54235-1495
Austin, Texas, 78701
Fort Collins, Colorado, 80524
Fort Thomas, Kentucky, 41075
Augusta, Georgia, 30912
Austin, Texas, 78731
Concord, California, 94520
Sunnyvale, California, 94086
Lancaster, South Carolina, 29720
Oconto Falls, Wisconsin, 54154
Chippewa Falls, Wisconsin, 54729
Ames, Iowa, 50010
Grand Island, Nebraska, 68803
Ann Arbor, Michigan, 48106
Bronx, New York, 10467
Ogden, Utah, 84403
Effingham, Illinois, 62401
Phoenix, Arizona, 85013
Grand Rapids, Michigan, 49503
Pinehurst, North Carolina, 28374
League City, Texas, 77573
Sioux Falls, South Dakota, 57104
Cincinnati, Ohio, 45219
Burien, Washington, 98166
Wausau, Wisconsin, 54401
Huntington, West Virginia, 25701
Richmond, Virginia, 23229
'Aiea, Hawaii, 96701
Cincinnati, Ohio, 45220
Des Moines, Iowa, 50314
Houston, Texas, 77030
Dearborn, Michigan, 48124
Pittsburgh, Pennsylvania, 15213
Rochester, Minnesota, 55905
Bronx, New York, 10461
Springfield, Illinois, 62702
Mishawaka, Indiana, 46545
Tyler, Texas, 75702
Charlottesville, Virginia, 22908
Billings, Montana, 59101
Galesburg, Illinois, 61401
Crown Point, Indiana, 46307
Muskegon, Michigan, 49444
Mayfield Heights, Ohio, 44124
Winston-Salem, North Carolina, 27103
Oconomowoc, Wisconsin, 53066
Cincinnati, Ohio, 45242
Fargo, North Dakota, 58122
Hanover, Pennsylvania, 17331
Dallas, Texas, 75246
Ann Arbor, Michigan, 48106
Iron Mountain, Michigan, 49801
Seattle, Washington, 98109
Mentor, Ohio, 44060
The Woodlands, Texas, 77380
San Francisco, California, 94115
Newark, Delaware, 19713
Santa Cruz, California, 95065
Houston, Texas, 77030
Atlanta, Georgia, 30322
Coon Rapids, Minnesota, 55433
Sacramento, California, 95817
Glenview, Illinois, 60026
Bethlehem, Pennsylvania, 18015
Sacramento, California, 95825
Stillwater, Minnesota, 55082
Pasadena, California, 91105
Tucson, Arizona, 85719
Rapid City, South Dakota, 57701
Reed City, Michigan, 49677
Warrenville, Illinois, 60555
Pontiac, Michigan, 48341
Abington, Pennsylvania, 19001
Stony Brook, New York, 11794
New York, New York, 10003
Huntsville, Alabama, 35805
Decatur, Illinois, 62526
Sioux Falls, South Dakota, 57105
Aurora, Illinois, 60504
Green Bay, Wisconsin, 54303
Boston, Massachusetts, 02215
Dallas, Texas, 75235
Chicago, Illinois, 60611
Roanoke, Virginia, 24016
San Francisco, California, 94110
Raleigh, North Carolina, 27609
Newark, Delaware, 19713
Livonia, Michigan, 48154
Great Falls, Montana, 59405
Wausau, Wisconsin, 54401
Indianapolis, Indiana, 46202
Marshfield, Wisconsin, 54449
Kewanee, Illinois, 61443
Meriden, Connecticut, 06451
New York, New York, 10029
Peoria, Illinois, 61615
Camden, New Jersey, 08103
Little Rock, Arkansas, 72205
Seneca, Pennsylvania, 16346
Clive, Iowa, 50325
La Porte, Indiana, 46350
Gig Harbor, Washington, 98335
Los Angeles, California, 90027
Ottawa, Illinois, 61350
Brooklyn, New York, 11215
Houston, Texas, 77026-1967
Conroe, Texas, 77384
Geneva, Illinois, 60134
Bennington, Vermont, 05201
Durham, North Carolina, 27710
American Fork, Utah, 84003
Akron, Ohio, 44304
Phoenix, Arizona, 85004
Mount Holly, New Jersey, 08060
Hartford, Connecticut, 06102
Atlanta, Georgia, 30308
Elkhart, Indiana, 46515
Mineola, New York, 11501
Honolulu, Hawaii, 96817
Springfield, Missouri, 65804
'Aiea, Hawaii, 96701
Rice Lake, Wisconsin, 54868
Urbana, Illinois, 61801
Jackson, Michigan, 49201
Elkhart, Indiana, 46514
Sarasota, Florida, 34239
Oakland, California, 94611
Mountain View, California, 94040
Charleston, South Carolina, 29425
Waterbury, Connecticut, 06708
North Haven, Connecticut, 06473
Stevens Point, Wisconsin, 54482
Houston, Texas, 77030
Berlin, Vermont, 05602
Bethesda, Maryland, 20889-5600
Longview, Texas, 75601
Omaha, Nebraska, 68198
Edgewood, Kentucky, 41017
Fort Worth, Texas, 76104
Los Angeles, California, 90033
Pittsburgh, Pennsylvania, 15237
Lansing, Michigan, 48912
Middletown, New Jersey, 07748
Boone, Iowa, 50036
Spartanburg, South Carolina, 29303
Rock Hill, South Carolina, 29732
Eau Claire, Wisconsin, 54701
Sylmar, California, 91342
Minneapolis, Minnesota, 55407
Seattle, Washington, 98109
New Haven, Connecticut, 06520
Monroe, Michigan, 48162
Warren, Michigan, 48093
Wright-Patterson Air Force Base, Ohio, 45433-5529
Edina, Minnesota, 55435
Grand Rapids, Michigan, 49503
Palo Alto, California, 94304
Pittsburgh, Pennsylvania, 15232
Richmond, Virginia, 23229
Jackson, Mississippi, 39216
Orange, California, 92868
Greer, South Carolina, 29651
Sturgeon Bay, Wisconsin, 54235
Traverse City, Michigan, 49684
Cleveland, Ohio, 44111
Decatur, Georgia, 30033
Goldsboro, North Carolina, 27534
Springfield, Illinois, 62702
Sugar Land, Texas, 77479
'Aiea, Hawaii, 96701
Rolla, Missouri, 65401
Toledo, Ohio, 43606
York, Pennsylvania, 17403
Sugar Land, Texas, 77479
West Chester, Pennsylvania, 19380
Buffalo, New York, 14263
Voorhees, New Jersey, 08043
Dayton, Ohio, 45406
Burlington, Vermont, 05405
Boston, Massachusetts, 02115
Summit, New Jersey, 07902
Webster, Texas, 77598
Guilford, Connecticut, 06437
Honolulu, Hawaii, 96813
San Jose, California, 95119
Springfield, Massachusetts, 01199
Aurora, Colorado, 80045
Las Vegas, Nevada, 89169
Effingham, Illinois, 62401
Chicago, Illinois, 60637
Morgantown, West Virginia, 26505
Pekin, Illinois, 61554
Savannah, Georgia, 31405
Salt Lake City, Utah, 84143
Worcester, Massachusetts, 01605
New York, New York, 10016
Winston-Salem, North Carolina, 27157
Brooklyn, New York, 11203
Bedford, Texas, 76022
Newark, Delaware, 19718
Troy, Michigan, 48085
New Britain, Connecticut, 06050
Salt Lake City, Utah, 84112
Murray, Utah, 84107
Morristown, New Jersey, 07960
Columbus, Ohio, 43219
Woodbury, Minnesota, 55125
Albany, New York, 12208
Mukwonago, Wisconsin, 53149
Honolulu, Hawaii, 96813
White Plains, New York, 10601
Hartford, Connecticut, 06105
Tucson, Arizona, 85719
Royal Oak, Michigan, 48073
Danville, Pennsylvania, 17822
Saint Petersburg, Florida, 33701
Derby, Connecticut, 06418
Saint George, Utah, 84770
Burlington, Vermont, 05401

Tracking Information

NCT #
NCT02065687
Collaborators
National Cancer Institute (NCI)
Investigators
  • Principal Investigator: Victoria L Bae-Jump NRG Oncology
  • Victoria L Bae-Jump NRG Oncology